Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours

NCT05120596 is registered in ClinicalTrials.gov with T3 Pharmaceuticals AG as lead sponsor.

NCT NCT05120596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05120596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours
Lead sponsor
T3 Pharmaceuticals AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 26, 2022
Completion date
October 15, 2027
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor